Does TRICARE Cover Avodart (Dutasteride)?

TRICARE Formulary Placement for Dutasteride

Generic dutasteride is listed on the TRICARE Uniform Formulary as a preferred medication for BPH, which means military beneficiaries can fill it at standard copay rates without prior authorization. Brand-name Avodart, by contrast, occupies a non-preferred or Tier 3 position, triggering higher out-of-pocket costs and, in many cases, a prior authorization requirement before the pharmacy will dispense it.

The Department of Defense Pharmacoeconomic Center (PEC) reviews drug classifications quarterly. Dutasteride has maintained its formulary position since the FDA approved it in November 2001 for treating symptomatic BPH in men with enlarged prostates. The drug works by inhibiting both type I and type II 5-alpha reductase isoenzymes, reducing dihydrotestosterone (DHT) levels by more than 90% at steady state [1]. This dual-isoenzyme inhibition distinguishes it from finasteride, which blocks only type II.

For active-duty service members filling prescriptions at military treatment facility (MTF) pharmacies, dutasteride carries zero copay. TRICARE Prime and TRICARE Select beneficiaries using the Express Scripts mail-order program (home delivery) pay $14 for a 90-day generic supply. Retail pharmacy copays for a 30-day supply are $14 for generic and $36 for preferred brand medications under TRICARE Prime [2].

A key distinction: TRICARE does not follow the same formulary logic as Medicare Part D or commercial plans. The Uniform Formulary is DoD-wide. If a drug appears on the Basic Core Formulary, every MTF pharmacy stocks it. Generic dutasteride meets this threshold. Brand Avodart does not.

Prior Authorization Criteria for Avodart on TRICARE

When a prescriber writes for brand-name Avodart instead of generic dutasteride, TRICARE's pharmacy benefit manager (currently Express Scripts) flags the claim. The prior authorization process requires documentation showing a clinical reason why the generic formulation is inadequate.

Approval criteria typically include one or more of the following: documented adverse reaction to generic dutasteride, therapeutic failure on the generic version with objective evidence (such as continued prostate volume increase on imaging), or a formulation-specific medical need (e.g., documented allergy to an inactive ingredient in the generic capsule). The prescribing provider must submit the request through the Express Scripts prior authorization portal or by fax, and decisions are returned within 72 hours for non-urgent requests [3].

The approval rate for brand-over-generic prior authorization requests on TRICARE tends to be low. Without a documented clinical rationale beyond preference, the request will be denied. This is consistent with DoD cost-containment policy, which saved the Military Health System an estimated $3.8 billion through generic substitution between 2016 and 2021 [4].

For prescribers: include pharmacy records showing dates and duration of generic dutasteride use, any documented side effects or lab changes, and a clear statement explaining why the brand formulation is medically necessary. Vague statements like "patient prefers brand" will not satisfy the criteria.

Step Therapy: Why TRICARE May Require Finasteride First

TRICARE employs step therapy protocols for 5-alpha reductase inhibitors. Before approving dutasteride, the plan may require evidence that the beneficiary tried and failed finasteride (Proscar), the older and less expensive drug in this class. This step therapy requirement applies most strictly to new prescriptions and is less commonly enforced for patients already stabilized on dutasteride.

The clinical basis for this policy rests on the CombAT trial (N=4,844), which compared dutasteride, tamsulosin, and their combination over four years. The combination of dutasteride plus tamsulosin reduced the relative risk of acute urinary retention or BPH-related surgery by 65.8% compared to tamsulosin alone at 4 years [5]. Dutasteride monotherapy reduced prostate volume by 28% at 2 years. Finasteride produces a similar 20-25% volume reduction in comparable trials, and the Proscar Long-Term Efficacy and Safety Study (PLESS) demonstrated a 57% reduction in acute urinary retention risk over 4 years [6].

From TRICARE's perspective, finasteride achieves clinically comparable outcomes at lower acquisition cost. The step therapy override becomes available once a beneficiary demonstrates finasteride intolerance or failure, defined as persistent symptoms after at least 6 months of continuous finasteride therapy, documented PSA changes suggesting inadequate DHT suppression, or adverse effects such as sexual dysfunction, breast tenderness, or mood changes.

Dr. Kevin McVary, former chair of the AUA BPH Guidelines Panel, has stated: "Both finasteride and dutasteride are effective 5-alpha reductase inhibitors for BPH. The choice between them should be individualized based on patient response and tolerability."

Off-Label Coverage: Dutasteride for Hair Loss

TRICARE does not routinely cover dutasteride for androgenetic alopecia (male pattern hair loss). The drug lacks an FDA-approved indication for this use, and TRICARE's pharmacy benefit excludes most cosmetic or lifestyle medications unless tied to a covered medical diagnosis.

The evidence base for dutasteride in hair loss is growing. Eun et al. (2010) conducted a randomized, double-blind trial comparing dutasteride 0.5 mg daily to finasteride 1 mg daily in 153 Korean men with androgenetic alopecia over 24 weeks. Dutasteride-treated patients showed statistically superior hair count increases: a mean change of +12.2 hairs/cm² in the target area compared to +4.7 hairs/cm² with finasteride (P<0.05) [7]. A larger phase III trial by Gubelin Harcha et al. (2014, N=917) confirmed dutasteride 0.5 mg was superior to finasteride 1 mg for change in target-area hair count at 24 weeks (+109.6 vs. +75.6 hairs, P<0.001) [8].

Despite this data, TRICARE classifies hair loss treatment as non-covered unless the condition results from a service-connected injury, burn, or medical treatment (such as chemotherapy-induced alopecia). Beneficiaries seeking coverage for dutasteride as a hair loss treatment should be prepared for a denial and should plan to file an appeal with supporting documentation from a dermatologist.

Dr. Wilma Bergfeld, former president of the American Academy of Dermatology, has noted: "Dutasteride's dual 5-alpha reductase inhibition produces more complete DHT suppression than finasteride, which may explain the superior hair count results seen in head-to-head trials."

How to Appeal a TRICARE Denial of Dutasteride

A denied claim for dutasteride on TRICARE follows a structured appeal process. The first level is an informal reconsideration request submitted to the TRICARE regional contractor (Humana Military for the East Region, Health Net Federal Services for the West Region). This must be filed within 90 days of the denial notice.

The appeal package should contain the following elements:

• A copy of the denial letter with the specific reason code
• A letter of medical necessity from the prescribing provider, detailing the diagnosis (ICD-10 code N40.1 for BPH with lower urinary tract symptoms, or L64.0 for androgenetic alopecia)
• Documentation of prior medication trials and their outcomes, including dates, doses, and reasons for discontinuation
• Relevant lab results (PSA levels, prostate volume measurements on ultrasound if available)
• Supporting clinical literature for off-label use cases

If the informal reconsideration is denied, the beneficiary may request a formal review by filing a written appeal within 60 days. This escalates to an independent review organization. For TRICARE for Life beneficiaries (those also enrolled in Medicare), the appeal follows Medicare Part B or Part D appeal pathways depending on how the claim was processed.

According to TRICARE's own published data, approximately 40-50% of pharmacy-related appeals result in a full or partial overturn when adequate clinical documentation is provided [9]. The most common reason for appeal failure is insufficient documentation rather than a clinical disagreement.

Cost Comparison: TRICARE vs. Cash Pay vs. Manufacturer Programs

The cost equation for dutasteride depends heavily on which TRICARE benefit pathway a beneficiary uses. Military treatment facility pharmacies dispense generic dutasteride at no cost. Mail-order through Express Scripts costs $14 for 90 days. Retail pharmacies charge $14 for a 30-day supply under TRICARE Prime.

Brand-name Avodart carries a manufacturer list price near $290 per month. The GoodRx cash price for generic dutasteride ranges from $15 to $35 for a 30-day supply, making it one of the most affordable branded-to-generic conversions in urology. For beneficiaries who face a TRICARE denial and choose to pay out of pocket, generic dutasteride purchased through cash-pay discount programs is often cheaper than a TRICARE non-formulary copay.

One important restriction: TRICARE beneficiaries cannot use manufacturer copay cards or savings coupons. Federal law (the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b) prohibits pharmaceutical manufacturers from offering copay assistance to beneficiaries of federal healthcare programs, including TRICARE, Medicare, and Medicaid [10]. Manufacturer patient assistance programs (PAPs) that provide free medication to uninsured or underinsured individuals also exclude TRICARE beneficiaries, since TRICARE is considered primary insurance.

The practical takeaway: generic dutasteride through TRICARE mail order is the most cost-effective option at $14 per 90 days. Beneficiaries paying out of pocket for any reason should use pharmacy discount tools to find the lowest generic cash price.

Dutasteride Safety Profile and Monitoring on TRICARE

TRICARE-covered prescriptions for dutasteride come with standard monitoring recommendations aligned with FDA labeling. Baseline PSA should be measured before starting therapy, and clinicians should be aware that dutasteride lowers PSA by approximately 50% within 3 to 6 months of treatment [1]. This PSA reduction must be accounted for in prostate cancer screening. The American Urological Association recommends doubling the measured PSA value in patients taking 5-alpha reductase inhibitors to estimate the "true" PSA level [11].

Sexual side effects are the most commonly reported adverse events. In the key ARIA trial (N=6,729), dutasteride was associated with erectile dysfunction in 6.0% vs. 3.7% for placebo, decreased libido in 3.3% vs. 1.6%, and gynecomastia in 1.3% vs. 0.4% [12]. These rates are consistent with the REDUCE trial (N=8,231), the largest randomized study of dutasteride, which followed men for four years [13].

TRICARE covers routine lab monitoring associated with dutasteride therapy, including PSA testing and metabolic panels, without separate authorization. Beneficiaries should confirm that their provider orders these labs under a covered diagnosis code to avoid out-of-pocket charges.

One clinical point warrants emphasis. Dutasteride has a long half-life of approximately 5 weeks at steady state. Effects on DHT suppression, side effects, and PSA readings persist for months after discontinuation. Women who are pregnant or may become pregnant should not handle crushed or broken dutasteride capsules due to the risk of fetal abnormality from dermal absorption [1].

TRICARE Prime vs. TRICARE Select: Coverage Differences

Both TRICARE Prime and TRICARE Select cover generic dutasteride as a formulary medication. The difference is copay structure, not drug access.

TRICARE Prime beneficiaries pay $0 at MTF pharmacies, $14 for 90 days via mail order, and $14 for 30 days at retail. TRICARE Select beneficiaries pay $0 at MTF pharmacies and $14 for 90 days via mail order, but retail copays are higher: $15 for generic and $43 for brand-name formulary drugs [2]. Non-formulary drugs under TRICARE Select carry a $60 retail copay for a 30-day supply.

TRICARE for Life (TFL) beneficiaries, who are Medicare-eligible retirees, have their prescriptions processed through Medicare Part D first. If Medicare Part D covers dutasteride on its formulary, TFL picks up the remaining cost share. This dual-coverage arrangement typically results in lower net costs than either program alone.

TRICARE Reserve Select (TRS) and TRICARE Young Adult (TYA) plans follow the same Uniform Formulary but have different cost-sharing percentages. TRS beneficiaries should verify their specific copay tier through the Express Scripts member portal or by calling the TRICARE pharmacy help line at 1-877-363-1303.